Clemens C Cyran1, Yanjun Fu, Victor Rogut, Bundit Chaopathomkul, Michael F Wendland, David M Shames, Robert C Brasch. 1. Center for Pharmaceutical and Molecular Imaging, Department of Radiology, University of California San Francisco, San Francisco, California; Department of Clinical Radiology, Laboratory for Experimental Radiology, University Hospitals Munich, Campus Grosshadern, Marchioninistrasse 15, 81377 Munich, Germany. Electronic address: Clemens.Cyran@med.lmu.de.
Abstract
RATIONALE AND OBJECTIVES: To assess the applicability of a novel macromolecular polyethylene glycol (PEG)-core gadolinium contrast agent for monitoring early antiangiogenic effects of bevacizumab using dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI). MATERIALS AND METHODS: Athymic rats (n = 26) implanted with subcutaneous human melanoma xenografts underwent DCE-MRI at 2.0 T using two different macromolecular contrast agents. The PEG core cascade polymer PEG12,000-Gen4-(Gd-DOTA)16, designed for clinical development, was compared to the prototype, animal-only, macromolecular contrast medium (MMCM) albumin-(Gd-DTPA)35. The treatment (n = 13) and control (n = 13) group was imaged at baseline and 24 hours after a single dose of bevacizumab (1 mg) or saline to quantitatively assess the endothelial-surface permeability constant (K(PS), μL⋅min⋅100 cm(3)) and the fractional plasma volume (fPV,%), using a two-compartment kinetic model. RESULTS: Mean K(PS) values, assessed with PEG12,000-Gen4-(Gd-DOTA)16, declined significantly (P < .05) from 29.5 ± 10 μL⋅min⋅100 cm(3) to 10.4 ± 7.8 μL⋅min⋅100 cm(3) by 24 hours after a single dose of bevacizumab. In parallel, K(PS) values quantified using the prototype MMCM albumin-(Gd-DTPA)35 showed an analogous, significant decline (P < .05) in the therapy group. No significant effects were detected on tumor vascularity or on microcirculatory parameters in the control group between the baseline and the follow-up scan at 24 hours. CONCLUSION: DCE-MRI enhanced with the novel MMCM PEG12,000-Gen4-(Gd-DOTA)16 was able to monitor the effects of bevacizumab on melanoma xenografts within 24 hours of a single application, validated by the prototype, animal-only albumin-(Gd-DTPA)35. PEG12,000-Gen4-(Gd-DOTA)16 may be a promising candidate for further clinical development as a macromolecular blood pool contrast MRI agent.
RATIONALE AND OBJECTIVES: To assess the applicability of a novel macromolecular polyethylene glycol (PEG)-core gadolinium contrast agent for monitoring early antiangiogenic effects of bevacizumab using dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI). MATERIALS AND METHODS: Athymic rats (n = 26) implanted with subcutaneous humanmelanoma xenografts underwent DCE-MRI at 2.0 T using two different macromolecular contrast agents. The PEG core cascade polymerPEG12,000-Gen4-(Gd-DOTA)16, designed for clinical development, was compared to the prototype, animal-only, macromolecular contrast medium (MMCM) albumin-(Gd-DTPA)35. The treatment (n = 13) and control (n = 13) group was imaged at baseline and 24 hours after a single dose of bevacizumab (1 mg) or saline to quantitatively assess the endothelial-surface permeability constant (K(PS), μL⋅min⋅100 cm(3)) and the fractional plasma volume (fPV,%), using a two-compartment kinetic model. RESULTS: Mean K(PS) values, assessed with PEG12,000-Gen4-(Gd-DOTA)16, declined significantly (P < .05) from 29.5 ± 10 μL⋅min⋅100 cm(3) to 10.4 ± 7.8 μL⋅min⋅100 cm(3) by 24 hours after a single dose of bevacizumab. In parallel, K(PS) values quantified using the prototype MMCM albumin-(Gd-DTPA)35 showed an analogous, significant decline (P < .05) in the therapy group. No significant effects were detected on tumor vascularity or on microcirculatory parameters in the control group between the baseline and the follow-up scan at 24 hours. CONCLUSION:DCE-MRI enhanced with the novel MMCMPEG12,000-Gen4-(Gd-DOTA)16 was able to monitor the effects of bevacizumab on melanoma xenografts within 24 hours of a single application, validated by the prototype, animal-only albumin-(Gd-DTPA)35. PEG12,000-Gen4-(Gd-DOTA)16 may be a promising candidate for further clinical development as a macromolecular blood pool contrast MRI agent.
Authors: C D Pham; T P Roberts; N van Bruggen; O Melnyk; J Mann; N Ferrara; R L Cohen; R C Brasch Journal: Cancer Invest Date: 1998 Impact factor: 2.176
Authors: T P Roberts; R C Brasch; H C Schwickert; D M Shames; C F vanDijke; M Stiskal; J S Mann; A Mühler; F Demsar Journal: Acad Radiol Date: 1996-08 Impact factor: 3.173
Authors: R Brasch; C Pham; D Shames; T Roberts; K van Dijke; N van Bruggen; J Mann; S Ostrowitzki; O Melnyk Journal: J Magn Reson Imaging Date: 1997 Jan-Feb Impact factor: 4.813
Authors: T M Grist; F R Korosec; D C Peters; S Witte; R C Walovitch; R P Dolan; W E Bridson; E K Yucel; C A Mistretta Journal: Radiology Date: 1998-05 Impact factor: 11.105
Authors: Karl Turetschek; Anda Preda; Viktor Novikov; Robert C Brasch; Hanns J Weinmann; Patrick Wunderbaldinger; Timothy P L Roberts Journal: J Magn Reson Imaging Date: 2004-07 Impact factor: 4.813
Authors: H F Dvorak; T M Sioussat; L F Brown; B Berse; J A Nagy; A Sotrel; E J Manseau; L Van de Water; D R Senger Journal: J Exp Med Date: 1991-11-01 Impact factor: 14.307
Authors: J Guo; J O Glass; M B McCarville; B L Shulkin; V M Daryani; C F Stewart; J Wu; S Mao; J R Dwek; L M Fayad; J E Madewell; F Navid; N C Daw; W E Reddick Journal: Br J Cancer Date: 2015-10-13 Impact factor: 7.640
Authors: Jessica Lohrke; Thomas Frenzel; Jan Endrikat; Filipe Caseiro Alves; Thomas M Grist; Meng Law; Jeong Min Lee; Tim Leiner; Kun-Cheng Li; Konstantin Nikolaou; Martin R Prince; Hans H Schild; Jeffrey C Weinreb; Kohki Yoshikawa; Hubertus Pietsch Journal: Adv Ther Date: 2016-01-25 Impact factor: 3.845